MA63525B1 - Compositions d'oligonucléotides et leurs procédés de préparation - Google Patents

Compositions d'oligonucléotides et leurs procédés de préparation

Info

Publication number
MA63525B1
MA63525B1 MA63525A MA63525A MA63525B1 MA 63525 B1 MA63525 B1 MA 63525B1 MA 63525 A MA63525 A MA 63525A MA 63525 A MA63525 A MA 63525A MA 63525 B1 MA63525 B1 MA 63525B1
Authority
MA
Morocco
Prior art keywords
free
amino group
bond
protected
dinucleotide
Prior art date
Application number
MA63525A
Other languages
English (en)
French (fr)
Other versions
MA63525A1 (fr
Inventor
Premchandran H. Ramiya
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of MA63525A1 publication Critical patent/MA63525A1/fr
Publication of MA63525B1 publication Critical patent/MA63525B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA63525A 2014-05-01 2015-04-29 Compositions d'oligonucléotides et leurs procédés de préparation MA63525B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US201562151909P 2015-04-23 2015-04-23

Publications (2)

Publication Number Publication Date
MA63525A1 MA63525A1 (fr) 2024-09-30
MA63525B1 true MA63525B1 (fr) 2025-02-28

Family

ID=54359301

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63525A MA63525B1 (fr) 2014-05-01 2015-04-29 Compositions d'oligonucléotides et leurs procédés de préparation

Country Status (33)

Country Link
US (6) US9796747B2 (enExample)
EP (2) EP4286519A3 (enExample)
JP (6) JP7040892B2 (enExample)
KR (4) KR20230088509A (enExample)
CN (3) CN117357548A (enExample)
AP (1) AP2016009489A0 (enExample)
AU (3) AU2015253158B2 (enExample)
BR (1) BR112016025196B1 (enExample)
CL (4) CL2016002749A1 (enExample)
DK (1) DK3137479T5 (enExample)
EA (1) EA034882B9 (enExample)
ES (1) ES2963740T3 (enExample)
FI (1) FI3137479T3 (enExample)
HR (1) HRP20231505T1 (enExample)
HU (1) HUE064289T2 (enExample)
IL (2) IL248044B (enExample)
JO (2) JOP20200257A1 (enExample)
LT (1) LT3137479T (enExample)
MA (1) MA63525B1 (enExample)
MX (2) MX382233B (enExample)
MY (2) MY178617A (enExample)
PE (1) PE20170147A1 (enExample)
PH (1) PH12016502080A1 (enExample)
PL (1) PL3137479T3 (enExample)
PT (1) PT3137479T (enExample)
RS (1) RS64860B1 (enExample)
SG (2) SG10201911086XA (enExample)
SI (1) SI3137479T1 (enExample)
SM (1) SMT202300405T1 (enExample)
TW (2) TWI709406B (enExample)
UA (1) UA126108C2 (enExample)
WO (1) WO2015168310A1 (enExample)
ZA (2) ZA201606624B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3296312B1 (en) 2004-07-02 2021-03-17 Geron Corporation Synthesis of protected 3'-amino 5'-phosphoramidite nucleoside monomers
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
DK3652187T3 (da) * 2017-07-10 2021-12-13 Geron Corp Forbedret fremgangsmåde til fremstilling af imetelstat
CN114845992A (zh) * 2019-10-28 2022-08-02 美国杰龙生物医药公司 无定形固体琥珀酰化的3-(脂肪酸酰胺基)-2-羟基-1-(受保护羟基)-丙烷盐及其制备方法
JP2022554244A (ja) 2019-10-28 2022-12-28 ジェロン・コーポレーション ３－パルミトイル－アミド－１，２－プロパンジオールおよび３－パルミトイル－アミド－２－ヒドロキシ－１－ジメトキシトリフェニルメチルエーテル－プロパンの結晶性固体ならびにそれらを作製および使用する方法
JP7657736B2 (ja) * 2020-01-08 2025-04-07 日東電工株式会社 セグメント型アミダイトを用いた核酸合成法
KR20250008345A (ko) 2023-07-07 2025-01-14 주식회사 엘지에너지솔루션 체결기구 및 체결기구를 포함하는 전지팩

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018015A1 (en) * 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
WO2002077184A2 (en) * 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
EP0462145B1 (en) 1989-03-07 1994-04-27 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
AU7759291A (en) 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
JP4281926B2 (ja) 1993-10-18 2009-06-17 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ ニューロンの生き残りを増加させる方法およびそれに有用な薬剤
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5965720A (en) 1994-03-18 1999-10-12 Lynx Therapeutics, Inc. Oligonucleotide N3'→P5' phosphoramidates
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
ES2251720T3 (es) 1994-07-07 2006-05-01 Geron Corporation Telomerasa de mamifero.
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
AU4101396A (en) 1994-11-07 1996-05-31 Hybridon, Inc. Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
EP3342425B1 (en) 2003-09-09 2019-12-18 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
EP3296312B1 (en) 2004-07-02 2021-03-17 Geron Corporation Synthesis of protected 3'-amino 5'-phosphoramidite nucleoside monomers
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
EP1812598A1 (en) * 2004-10-18 2007-08-01 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP4474480A2 (en) 2006-10-30 2024-12-11 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2008094640A2 (en) * 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018015A1 (en) * 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
US20070037770A1 (en) * 1999-09-10 2007-02-15 Sergei Gryaznov Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
WO2002077184A2 (en) * 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates

Also Published As

Publication number Publication date
AU2020201707A1 (en) 2020-03-26
EA034882B9 (ru) 2020-07-13
US20240150391A1 (en) 2024-05-09
JP7308309B2 (ja) 2023-07-13
US9796747B2 (en) 2017-10-24
HRP20231505T1 (hr) 2024-03-01
CL2018001212A1 (es) 2018-08-03
SI3137479T1 (sl) 2023-11-30
HUE064289T2 (hu) 2024-02-28
AU2022203273A1 (en) 2022-06-02
KR20240144488A (ko) 2024-10-02
TWI709406B (zh) 2020-11-11
RS64860B1 (sr) 2023-12-29
JP2017514479A (ja) 2017-06-08
TW202017574A (zh) 2020-05-16
IL268570B (en) 2021-10-31
JP2020050670A (ja) 2020-04-02
BR112016025196B1 (pt) 2022-08-02
FI3137479T3 (fi) 2023-11-28
KR102316282B1 (ko) 2021-10-25
US20220306676A1 (en) 2022-09-29
EA034882B1 (ru) 2020-04-01
MA63525A1 (fr) 2024-09-30
MX2016014178A (es) 2017-05-04
AU2015253158A1 (en) 2016-10-20
JOP20200257A1 (ar) 2017-06-16
JP7040892B2 (ja) 2022-03-23
CL2022000202A1 (es) 2023-02-10
PT3137479T (pt) 2023-11-30
IL248044A0 (en) 2016-11-30
JP2022044679A (ja) 2022-03-17
JP2018131453A (ja) 2018-08-23
CN117357548A (zh) 2024-01-09
US20180016293A1 (en) 2018-01-18
US20150337314A1 (en) 2015-11-26
US11739114B2 (en) 2023-08-29
US10392418B2 (en) 2019-08-27
CL2016002749A1 (es) 2017-04-28
DK3137479T3 (da) 2023-11-20
MX382233B (es) 2025-03-13
CN106459134B (zh) 2020-02-18
PH12016502080A1 (en) 2017-01-09
DK3137479T5 (da) 2024-10-14
US11299511B2 (en) 2022-04-12
KR20210130822A (ko) 2021-11-01
KR20230088509A (ko) 2023-06-19
AP2016009489A0 (en) 2016-10-31
NZ763996A (en) 2021-03-26
US20180016294A1 (en) 2018-01-18
EP4286519A3 (en) 2024-02-28
PL3137479T3 (pl) 2024-02-26
TW201622732A (zh) 2016-07-01
MY178617A (en) 2020-10-19
EP3137479A1 (en) 2017-03-08
WO2015168310A1 (en) 2015-11-05
EP3137479A4 (en) 2018-02-07
AU2015253158B2 (en) 2019-12-12
AU2020201707B2 (en) 2022-02-17
CN111228288B (zh) 2023-10-20
CA2943888A1 (en) 2015-11-05
EP3137479B1 (en) 2023-08-30
SG11201608226YA (en) 2016-10-28
ZA201606624B (en) 2020-12-23
KR102707216B1 (ko) 2024-09-19
UA126108C2 (uk) 2022-08-17
SMT202300405T1 (it) 2024-01-10
KR20160147768A (ko) 2016-12-23
MX2021004932A (es) 2021-08-16
IL268570A (en) 2019-09-26
CL2018001213A1 (es) 2018-08-03
IL248044B (en) 2019-08-29
TWI712413B (zh) 2020-12-11
MY196927A (en) 2023-05-11
JP7736489B2 (ja) 2025-09-09
EP4286519A2 (en) 2023-12-06
JO3767B1 (ar) 2021-01-31
PE20170147A1 (es) 2017-04-12
ZA202005857B (en) 2024-01-31
CN111228288A (zh) 2020-06-05
SG10201911086XA (en) 2020-01-30
EA201691786A1 (ru) 2017-04-28
NZ724764A (en) 2021-02-26
JP2021182946A (ja) 2021-12-02
BR112016025196A2 (pt) 2017-12-12
CN106459134A (zh) 2017-02-22
US20250011359A1 (en) 2025-01-09
JP2023073510A (ja) 2023-05-25
ES2963740T3 (es) 2024-04-01
LT3137479T (lt) 2023-10-10

Similar Documents

Publication Publication Date Title
MA63525B1 (fr) Compositions d'oligonucléotides et leurs procédés de préparation
EA201690274A1 (ru) Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов
WO2008069906A3 (en) Digital expression of gene analysis
MX2018013367A (es) Metodos para etiquetar bibliotecas codificadas por adn.
MX2009005896A (es) Proceso y aparato para preparar metacrilatos de alquilo.
WO2022084331A3 (en) Novel ligands for asialoglycoprotein receptor
DE602006012971D1 (de) Vermittelter chemie
RU2019119833A (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННАЯ миРНК
Kim et al. Degron-based bioPROTACs for controlling signaling in CAR T cells
UA99793C2 (ru) Набор для определения вируса гепатита в
MA59673A1 (fr) Compositions d'oligonucléotides et leurs procédés de préparation
ATE555076T1 (de) Verfahren zur herstellung von bronopol
ZA202110555B (en) Improved process for preparing imetelstat
WO2011067450A8 (es) Soportes biofuncionalizados covalentemente
EA202090282A1 (ru) Композиции олигонуклеотидов и способы их получения
MX2010012061A (es) Método para la detección del hongo fitopatógeno colletotrichum capsici utilizando la reacción en cadena de la polimerasa (pcr).
UA54336U (ru) Способ выявления рнк вируса геморрагической септицемии форели при помощи обратно - транскриптазной полимеразной цепной реакции
Куклин C vs. P
UA51551U (uk) Спосіб виявлення рнк ентеровірусів свиней а методом зворотнотранскриптазної полімеразної ланцюгової реакції
MX345865B (es) Equipo y metodo para la deteccion del rubulavirus porcino.
MY194293A (en) A method for identifying hiv-1 variants